// App-Quantinova.ai

P1374 : EASIX ASSESSED AT 1 YEAR AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION PREDICTS THE ONSET OF SUBSEQUENT NON-RELAPSE MORTALITY

Researchers

Presenter

  • Rui Takeda

Principal Investigators

  • Yasuhiko Shibasaki

  • Takayuki Katagiri

  • Kyoko Fuse

  • Hirohito Sone

  • Masayoshi Masuko

Medical Centers

  • Division of Hematopoietic Cell Transplantation,Niigata University Hospital, Niigat

  • Division of Hematopoietic Cell Transplantation,Niigata University Hospital, Niigat

  • Department of Hematology,

  • Department of Hematology, Niigata University Faculty of Medicine, Niigata, Japan

  • Department of Hematology, Niigata University Faculty of Medicine, Niigata, Japan

  • Department of Hematology, Niigata University Faculty of Medicine, Niigata, Japan

  • Division of Hematopoietic Cell Transplantation,Niigata University Hospital, Niigat

  • Division of Hematopoietic Cell Transplantation,Niigata University Hospital, Niigat

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute myelocytic leukemia

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved